Clinical Trial Results:
Intratumoral Influenza Vaccine for Early Colorectal Cancer
Summary
|
|
EudraCT number |
2020-000725-27 |
Trial protocol |
DK |
Global end of trial date |
01 Sep 2021
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
28 Jun 2023
|
First version publication date |
28 Jun 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
2020-000725-27
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Zealand University Hospital
|
||
Sponsor organisation address |
LYkkebækvej 1, Køge, Denmark,
|
||
Public contact |
Research fellow, Center for Surgical Science, Department of Surgery, Zealand University Hospital, 0045 31429929, mgog@regionsjaelland.dk
|
||
Scientific contact |
Research fellow, Center for Surgical Science, Department of Surgery, Zealand University Hospital, 0045 31429929, mgog@regionsjaelland.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Feb 2023
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
01 Sep 2021
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Sep 2021
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
Primary:
To investigate if intratumoral influenza vaccine is a safe treatment modality for tumor down staging prior to intended curative surgery in patients undergoing treatment for colorectal cancer.
|
||
Protection of trial subjects |
Treated in routine care
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
25 Feb 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 10
|
||
Worldwide total number of subjects |
10
|
||
EEA total number of subjects |
10
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
2
|
||
From 65 to 84 years |
8
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
Patients were recruited after the colorectal cancer MDT conference | ||||||
Pre-assignment
|
|||||||
Screening details |
Patients were screened at the colorectal cancer MDT conference | ||||||
Period 1
|
|||||||
Period 1 title |
Full study (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
This was a non-blinded single arm study
|
||||||
Arms
|
|||||||
Arm title
|
Active | ||||||
Arm description |
Treatment with intratumoral influenza vaccine | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
InfluVacTetra
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Concentrate and solvent for solution for injection/infusion
|
||||||
Routes of administration |
Intratumoral use
|
||||||
Dosage and administration details |
A single dose influenza vaccine (50 microliter) that was mixed with 150 microliter saline
|
||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Full study
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full analysis
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Baseline characteristics
Tumor-infiltrating lymphocytes
mRNA gene expression
Spatial protein expression
FLOW analysis of blood
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Active
|
||
Reporting group description |
Treatment with intratumoral influenza vaccine | ||
Subject analysis set title |
Full analysis
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Baseline characteristics
Tumor-infiltrating lymphocytes
mRNA gene expression
Spatial protein expression
FLOW analysis of blood
|
|
||||||||||||||||
End point title |
Safety of treatment (CTCAE v4) | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
Day 0-14
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Confidence interval for adverse events | |||||||||||||||
Comparison groups |
Active v Full analysis
|
|||||||||||||||
Number of subjects included in analysis |
20
|
|||||||||||||||
Analysis specification |
Post-hoc
|
|||||||||||||||
Analysis type |
other [1] | |||||||||||||||
Method |
||||||||||||||||
Parameter type |
Confidence interval | |||||||||||||||
Point estimate |
10
|
|||||||||||||||
Confidence interval |
||||||||||||||||
level |
95% | |||||||||||||||
sides |
2-sided
|
|||||||||||||||
lower limit |
0 | |||||||||||||||
upper limit |
30 | |||||||||||||||
Notes [1] - The investigators performed af statistical analysis of the confidence interval for adverse events as specified in "Simon, S. Confidence interval with zero events. http://new.pmean.com/zero-events/ (2001)" |
|
|||||||||||||||||
Adverse events information
|
|||||||||||||||||
Timeframe for reporting adverse events |
Day 0-14
|
||||||||||||||||
Adverse event reporting additional description |
CTCAE v4
|
||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||
Dictionary name |
CTCAE | ||||||||||||||||
Dictionary version |
4
|
||||||||||||||||
Reporting groups
|
|||||||||||||||||
Reporting group title |
Experimental arm
|
||||||||||||||||
Reporting group description |
- | ||||||||||||||||
|
|||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |